GSA Capital Partners’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-4,542
| Closed | -$422K | – | 1982 |
|
|
2021
Q4 | $422K | Sell |
4,542
-27,140
| -86% | -$1.79M | 0.05% | 707 |
|
|
2021
Q3 | $1.89M | Buy |
+31,682
| New | +$1.87M | 0.19% | 71 |
|
|
2021
Q2 | – | Sell |
-25,186
| Closed | -$1.75M | – | 1714 |
|
|
2021
Q1 | $1.75M | Buy |
25,186
+21,986
| +687% | +$1.69M | 0.29% | 60 |
|
|
2020
Q4 | $246K | Buy |
+3,200
| New | +$240K | 0.04% | 859 |
|
|
2020
Q1 | – | Sell |
-6,813
| Closed | -$309K | – | 1718 |
|
|
2019
Q4 | $309K | Buy |
6,813
+1,013
| +17% | +$47.9K | 0.04% | 1005 |
|
|
2019
Q3 | $265K | Buy |
+5,800
| New | +$326K | 0.04% | 1008 |
|
|
2018
Q2 | – | Sell |
-12,154
| Closed | -$480K | – | 2026 |
|
|
2018
Q1 | $480K | Sell |
12,154
-1,726
| -12% | -$67.1K | 0.03% | 1093 |
|
|
2017
Q4 | $472K | Sell |
13,880
-13,704
| -50% | -$390K | 0.03% | 969 |
|
|
2017
Q3 | $703K | Sell |
27,584
-71,820
| -72% | -$1.65M | 0.05% | 743 |
|
|
2017
Q2 | $1.68M | Buy |
+99,404
| New | +$1.36M | 0.11% | 229 |
|
|
2015
Q1 | – | Sell |
-2,180
| Closed | -$76K | – | 2257 |
|
|
2014
Q4 | $76K | Buy |
+2,180
| New | +$88.5K | 0.01% | 1612 |
|
|
2014
Q3 | – | Sell |
-3,175
| Closed | -$186K | – | 1989 |
|
|
2014
Q2 | $186K | Buy |
+3,175
| New | +$200K | 0.01% | 1648 |
|
|
2014
Q1 | – | Sell |
-1,214
| Closed | -$71K | – | 1869 |
|
|
2013
Q4 | $71K | Sell |
1,214
-2,905
| -71% | -$152K | 0.01% | 1589 |
|
|
2013
Q3 | $217K | Buy |
+4,119
| New | +$277K | 0.02% | 1350 |
|
GSA Capital Partners's ARNA Position: Q1 2022 in Review
GSA Capital Partners sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 4,542 shares — an estimated $422K sold.
GSA Capital Partners first reported a position in ARNA in Q3 2013 and held it in 14 quarters. The position peaked at $1.89M in Q3 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- GSA Capital Partners reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- GSA Capital Partners sold 4,542 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $422K.
- GSA Capital Partners first reported a position in Arena Pharmaceuticals Inc in Q3 2013 and held it in 14 quarters.
- GSA Capital Partners's Arena Pharmaceuticals Inc position peaked at $1.89M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.